['gastric adenocarcinoma']
['andecaliximab', 'placebo', 'leucovorin', '5-fluorouracil', 'oxaliplatin']

        Key Inclusion Criteria:

          -  Adults with histologically confirmed adenocarcinoma of the stomach or gastroesophageal
             junction that is inoperable, locally advanced or metastatic and not amenable to
             curative therapy

          -  Adequate hematologic, liver, coagulation and kidney function

          -  Eastern Cooperative Oncology Group (ECOG) ≤ 1

          -  Evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1

        Key Exclusion Criteria:

          -  Previous chemotherapy for locally advanced or metastatic gastric cancer.

          -  Human Epidermal Growth Factor Receptor 2 (HER2)-positive gastric cancer

          -  HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection

          -  Pregnant or breast feeding women

          -  Individuals with known or suspected central nervous system metastases or individuals
             requiring chronic daily treatment with oral corticosteroids

          -  Grade ≥ 2 peripheral neuropathy

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      